We indeed performed immunohistochemical staining for CD66b and CD8 in bladder cancer and prostate cancer specimens, but found no significant correlations between the number of immunoreactive immune cells and patient outcomes (unpublished data). This evidence concerns the gene CD8A and prostate cancer.